Pharmacodynamic model of topotecan-induced time course of neutropenia.

Pharmacodynamic measures of neutropenia, such as absolute neutrophil count at nadir and neutrophil survival fraction, may not reflect the overall time course of neutropenia. We developed a pharmacokinetic-pharmacodynamic model to describe and quantify the time course of neutropenia after administration of topotecan to children and to compare this with nonhuman primates (NHPs) as a potential preclinical model of neutropenia. Topotecan was administered as a 30-min infusion daily for 5 days, repeated every 21 days. As part of a Phase I Pediatric Oncology Group study, topotecan was administered at 1.4 and 1.7 mg/m(2)/day without filgrastim (POG), and at 1.7, 2, and 2.4 mg/m(2)/day with filgrastim (POG+G). In NHPs, topotecan was administered at 5, 10, and 20 mg/m(2)/day without filgrastim. A pharmacokinetic-pharmacodynamic model was fit to profiles of topotecan lactone plasma concentrations and neutrophil survival fraction from cycle 1 and used to calculate topotecan lactone area under the plasma concentration-versus-time curve from 0 to 120 h (AUC(LAC)) and the area between the baseline and treatment-related neutrophil survival fraction (ABC) from 0 to 700 h. The mean +/- SD neutrophil survival fraction at nadir for the POG, POG+G, and NHP groups was 0.12 +/- 0.09, 0.11 +/- 0.17, and 0.09 +/- 0.08, respectively (P > 0.05). The mean +/- SD for the ratio of ABC to AUC(LAC) for the POG and NHP groups was 1.02 +/- 0.38 and 0.16 +/- 0.09, respectively (P < 0.05). The model estimate of ABC and the ratio of ABC to AUC(LAC) in children and NHPs may better reflect sensitivity to chemotherapy-induced neutropenia.

[1]  A. Farese,et al.  Myelopoietin, a chimeric agonist of human interleukin 3 and granulocyte colony-stimulating factor receptors, mobilizes CD34+ cells that rapidly engraft lethally x-irradiated nonhuman primates. , 1999, Experimental hematology.

[2]  K. Kohn,et al.  Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors , 1994 .

[3]  L. Grochow,et al.  Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. , 1996, Journal of the National Cancer Institute.

[4]  P. Houghton,et al.  Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. , 1998, Journal of the National Cancer Institute.

[5]  H. Hansen,et al.  Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Meyer,et al.  Analysis of segmental phosphate absorption in intact rats. A compartmental analysis approach. , 1993, The Journal of clinical investigation.

[7]  Lieschke Gj,et al.  Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). , 1992, The New England journal of medicine.

[8]  M. Egorin,et al.  The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  M. Kris,et al.  Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. , 1994, The New England journal of medicine.

[10]  M C Mackey,et al.  Cyclical neutropenia and other periodic hematological disorders: a review of mechanisms and mathematical models. , 1998, Blood.

[11]  J. Kurtzberg,et al.  Phase I Trial and Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Topotecan Using a Five‐Day Course in Children with Refractory Solid Tumors: A Pediatric Oncology Group Study , 1996, Journal of pediatric hematology/oncology.

[12]  A. Karim.  The pharmacokinetics of Norpace. , 1975, Angiology.

[13]  P. Pizzo.  Granulocytopenia and cancer therapy: Past problems, current solutions, future challenges , 1984, Cancer.

[14]  R. Donehower,et al.  A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  L. Grochow,et al.  Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Swisher,et al.  Topotecan in platinum- and paclitaxel-resistant ovarian cancer. , 1997, Gynecologic oncology.

[17]  A. van der Gaast,et al.  What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 days. , 1992, Seminars in oncology.

[18]  P. Pizzo,et al.  Management of fever in patients with cancer and treatment-induced neutropenia. , 1993, The New England journal of medicine.

[19]  H. Rosing,et al.  High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. , 1995, Journal of chromatography. B, Biomedical applications.

[20]  P. Langenberg,et al.  Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  N. Saijo,et al.  Indirect‐response model for the time course of leukopenia with anticancer drugs , 1998, Clinical pharmacology and therapeutics.

[22]  P. Houghton,et al.  A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  G. Bonadonna,et al.  Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Baum,et al.  Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression. , 2000, Blood.

[25]  R. Parchment,et al.  Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro , 1997, Cancer Chemotherapy and Pharmacology.

[26]  J. Serody.  Fever in immunocompromised patients. , 2000, The New England journal of medicine.

[27]  M. Ratain.  Therapeutic relevance of pharmacokinetics and pharmacodynamics. , 1992, Seminars in oncology.